[1] 杨雄波, 王宗明, 张英, 等. 甲磺酸伊马替尼致慢性苔藓样角化病样药疹[J]. 临床皮肤科杂志, 2020, 49(10): 621-624.
[2] 陈晓颖, 陈力, 姚星宇. 甲磺酸伊马替尼致扁平苔癣样药疹1例并文献复习[J]. 中国中西医结合皮肤性病学杂志, 2019, 18(5): 482-483.
[3] 冯燕艳, 施若非, 郑捷. 甲磺酸伊马替尼致苔藓样药疹2例[J]. 中国麻风皮肤病杂志, 2014, 30(7): 434-435.
[4] 胡彩霞, 冯佳, 张国强, 等. 甲磺酸伊马替尼致扁平苔藓样药疹1例及文献复习[J]. 中国皮肤性病学杂志, 2015, 29(11): 1177-1179.
[5] SUDHA R, VETRICHEVVEL T P, KRISHNARATHNAM K, et al. Imatinib induced lichen planus[J]. Indian J Dermatol, 2011, 56(3):351-352.
[6] YELISETTI A, CHANDRASEKARAN N D, MAVALAVAN V M D, et al. Imatinib-induced lichen planus in chronic myeloid leukemia: a case series[J]. Cureus, 2023, 15(5):e39064.
[7] FRIOUI R, MOKNI S, TABKA M, et al. Inverse lichen planus and palmoplantar keratoderma induced by imatinib mesylate[J]. Int J Dermatol, 2023, 62(1):e44-e45.
[8] CALLEJA ALGARRA A, ARAGÓN MIGUEL R, VELASCO TAMARIZ V, et al. Lichen planopilaris related to imatinib therapy with good response to oral doxycycline[J]. Dermatol Ther, 2020, 33(4):e13465.
[9] ALEXANDRIS D, ALEVIZOPOULOS N, MARINOS L, et al. Lichenoid drug eruption associated with imatinib mesylate therapy[J]. J Oncol Pharm Pract, 2023, 29(1):252-257.
[10] GHOSH S K. Generalized lichenoid drug eruption associated with imatinib mesylate therapy[J]. Indian J Dermatol, 2013, 58(5):388-392.
[11] KURAISHI N, NAGAI Y, HASEGAWA M, et al. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature[J]. Acta Derm Venereol, 2010, 90(1):73-76.
[12] MARTÍNEZ DE LAGRÁN Z, GONZÁLEZ-HERMOSA M A, BLAYA-ALVAREZ B, et al. A case of lichen planus associated to treatment with imatinib[J]. Med Clin: Barc, 2009, 133(20):805-806.
[13] KALIYADAN F, GANESAN T S. Lichen planus associated with imatinib mesylate[J]. Indian J Dermatol Venereol Leprol, 2009, 75(5):527-528.
[14] ENA P, CHIAROLINI F, SIDDI G M, et al. Oral lichenoid eruption secondary to imatinib (Glivec)[J]. J Dermatolog Treat, 2004, 15(4):253-255.
[15] ROUX C, BOISSEAU-GARSAUD A M, SAINT-CYR I, et al. Lichenoid cutaneous reaction to imatinib[J]. Ann Dermatol Venereol, 2004, 131(6-7 Pt 1):571-573.
[16] SOLIMANI F, FORCHHAMMER S, SCHLOEGL A, et al. Lichen planus-a clinical guide[J]. J Dtsch Dermatol Ges, 2021, 19(6): 864-882.
[17] BOCH K, LANGAN E A, KRIDIN K, et al. Lichen planus[J]. Front Med: Lausanne, 2021, 8: 737813.
[18] 谢辉, 董宿利, 王新慧, 等. 扁平苔藓病因及发病机制研究进展[J]. 皮肤病与性病, 2021, 43(2): 179-180.
[19] VIČIĆ M, HLAČA N, KAŠTELAN M, et al. Comprehensive insight into lichen planus immunopathogenesis[J]. Int J Mol Sci, 2023, 24(3): 3038.
[20] PIETSCHKE K, HOLSTEIN J, MEIER K, et al. The inflammation in cutaneous lichen planus is dominated by IFN-γ and IL-21-A basis for therapeutic JAK1 inhibition[J]. Exp Dermatol, 2021, 30(2): 262-270.
[21] FIOCCO Z, KUPF S, PATZAK L, et al. Quality of life and psychopathology in lichen planus: a neglected disease burden[J]. Acta Derm Venereol, 2021, 101(12): adv00619.
[22] CHOLEWA K, MITAS K, ZAREMBA B, et al. Current review of conections between lichen planus and mental disorders[J]. Journal of Education, Health and Sport, 2020, 10(3): 57-65.
[23] DOROZHENOK I Y U, SNARSKAYA E S, MIKHAILOVA M. Lichen planus and itch-related psychosomatic disorders[J]. Russian Journal of Skin and Venereal Diseases, 2022, 24(6): 543-551.
[24] DIOP A, LY F, NDIAYE M T, et al. Epidemiology, clinical features, and associated factors in 78 cases of lichen planus on black skin[J]. Int J Dermatol, 2020, 59(2): 137-142.
[25] RESCHKE R, MOCKENHAUPT M, SIMON J C, et al. Severe bullous skin eruptions on checkpoint inhibitor therapy-in most cases severe bullous lichenoid drug eruptions[J]. J Dtsch Dermatol Ges, 2019, 17(9):942-948.
[26] SHAH R R, BHATE C, HERNANDEZ A, et al. Lichen planus pemphigoides: a unique form of bullous and lichenoid eruptions secondary to nivolumab[J]. Dermatol Ther, 2022, 35(5):e15432.
[27] 王亚男, 渠涛, 李丽. β受体阻滞剂致扁平苔藓样药疹一例[J]. 中国麻风皮肤病杂志, 2018, 34(6): 360-361.
[28] 范洪斌. 雷米封致扁平苔藓样药疹1例[J]. 临床皮肤科杂志, 1995,24(2): 80.
[29] 王榕, 李琳, 张峻岭. 紫杉醇致扁平苔藓样药疹1例[J]. 中国皮肤性病学杂志, 2020, 34(7): 827-829.
[30] LAI Y C, YEW Y W. Lichen planus and lichenoid drug eruption after vaccination[J]. Cutis, 2017, 100(6):E6-E20.
[31] MAUL J T, GUILLET C, OSCHMANN A, et al. Cutaneous lichenoid drug eruptions: a narrative review evaluating demographics, clinical features and culprit medications[J]. J Eur Acad Dermatol Venereol, 2023, 37(5):965-975.
[32] 岳欣, 胡均, 王家仓. 甲磺酸伊马替尼治疗手术无法切除的晚期胃肠间质瘤[J]. 中国肿瘤临床, 2016, 43(23): 1049-1052.
[33] HUANG W, LI J, QIU F, et al. Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: a case report[J]. J Clin Pharm Ther, 2020, 45(4):856-862.
[34] 刘白, 李军友, 骆志成. 甲磺酸伊马替尼致红皮病型药疹1例[J]. 中国皮肤性病学杂志, 2023, 37(6): 715-717.
[35] 陈薇, 韩世新, 史航, 等. 甲磺酸伊马替尼诱发扁平苔藓样药疹1例[J]. 中国皮肤性病学杂志, 2015, 29(12): 1280-1281.
[36] 刘丽丽, 姚立娟, 卞海林, 等. 甲磺酸伊马替尼片致剥脱性皮炎1例[J]. 药物流行病学杂志, 2020, 29(5): 367-368.
[37] ALMHEIRAT Y, BOUABDALLA S, DAFLAOUI H, et al. Imatinib-induced lichen planus and lichenoid drug eruption: a report of three cases[J]. J Cutan Pathol, 2023, 50(5):415-419.
[38] OH S H, BYUN H J, OH S J, et al. Olmutinib induced lichen planus like eruption[J]. Ann Dermatol, 2018, 30(4): 451-453.
[39] LUNGE S, BHISE R. Imatinib mesylate induced erythroderma[J]. J Assoc Physicians India, 2018, 66(12):79-80.
[40] LEITÃO J R, VALENTE N Y S, KAKIZAKI P, et al. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib[J]. An Bras Dermatol, 2016, 91(5 suppl 1):45-47.
[41] LAHOUEL I, BEN SALAH N, ROUATBI J, et al. Nilotinib-induced lichen planopilaris[J]. Int J Dermatol, 2022, 61(1): e37-e38.
[42] KUMARASINGHE S P W, PANDYA A, CHANDRAN V, et al. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl’s melanosis[J]. Int J Dermatol, 2019, 58(3): 263-272.
[43] SARKAR R, VINAY K, BISHNOI A, et al. A Delphi consensus on the nomenclature and diagnosis of lichen planus pigmentosus and related entities[J]. Indian J Dermatol Venereol Leprol, 2023, 89(1): 41-46. |
